Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

The Discovery and Hit-to-Lead Optimization of Tricyclic Sulfonamides as Potent and Efficacious Potentiators of Glycine Receptors.

Bregman H, Simard JR, Andrews KL, Ayube S, Chen H, Gunaydin H, Guzman-Perez A, Hu J, Huang L, Huang X, Krolikowski PH, Lehto SG, Lewis RT, Michelsen K, Pegman P, Plant MH, Shaffer PL, Teffera Y, Yi S, Zhang M, Gingras J, DiMauro EF.

J Med Chem. 2017 Feb 9;60(3):1105-1125. doi: 10.1021/acs.jmedchem.6b01496. Epub 2016 Dec 21.

PMID:
28001399
2.

Corrigendum to "Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling" [Bioorg. Med. Chem. 24 (2016) 2215-2234].

Liu L, Lee MR, Kim JL, Whittington DA, Bregman H, Hua Z, Lewis RT, Martin MW, Nishimura N, Potashman M, Yang K, Yi S, Vaida KR, Epstein LF, Babij C, Fernando M, Carnahan J, Norman MH.

Bioorg Med Chem. 2016 Jul 1;24(13):3093. doi: 10.1016/j.bmc.2016.05.014. Epub 2016 May 24. No abstract available.

PMID:
27234892
3.

Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.

Liu L, Lee MR, Kim JL, Whittington DA, Bregman H, Hua Z, Lewis RT, Martin MW, Nishimura N, Potashman M, Yang K, Yi S, Vaida KR, Epstein LF, Babij C, Fernando M, Carnahan J, Norman MH.

Bioorg Med Chem. 2016 May 15;24(10):2215-34. doi: 10.1016/j.bmc.2016.03.055. Epub 2016 Apr 13. Erratum in: Bioorg Med Chem. 2016 Jul 1;24(13):3093.

PMID:
27085672
4.

Identification of potent and selective MTH1 inhibitors.

Petrocchi A, Leo E, Reyna NJ, Hamilton MM, Shi X, Parker CA, Mseeh F, Bardenhagen JP, Leonard P, Cross JB, Huang S, Jiang Y, Cardozo M, Draetta G, Marszalek JR, Toniatti C, Jones P, Lewis RT.

Bioorg Med Chem Lett. 2016 Mar 15;26(6):1503-1507. doi: 10.1016/j.bmcl.2016.02.026. Epub 2016 Feb 11.

PMID:
26898335
5.

A multi-dimensional experiment for characterization of pore structure heterogeneity using NMR.

Lewis RT, Seland JG.

J Magn Reson. 2016 Feb;263:19-32. doi: 10.1016/j.jmr.2015.11.016. Epub 2015 Dec 30.

PMID:
26773523
6.

Characterising oil and water in porous media using decay due to diffusion in the internal field.

Lewis RT, Djurhuus K, Seland JG.

J Magn Reson. 2015 Oct;259:1-9. doi: 10.1016/j.jmr.2015.07.004. Epub 2015 Jul 21.

PMID:
26254732
7.

Novel emergency management of descending colon cancer presenting with retroperitoneal perforation.

Datta J, Caplow JA, Lewis RT, Braslow BM.

J Emerg Trauma Shock. 2014 Jan;7(1):55-6. doi: 10.4103/0974-2700.125643. No abstract available.

8.

Surgical treatment of anorectal crohn disease.

Lewis RT, Bleier JI.

Clin Colon Rectal Surg. 2013 Jun;26(2):90-9. doi: 10.1055/s-0033-1348047. Review.

9.

Long-range surface-induced water structures and the effect of 1-butanol studied by 1H nuclear magnetic resonance.

Totland C, Lewis RT, Nerdal W.

Langmuir. 2013 Sep 3;29(35):11055-61. doi: 10.1021/la401972g. Epub 2013 Aug 22.

PMID:
23937632
10.

Invited commentary.

Goldberg SM, Lewis RT.

Colorectal Dis. 2013 Jul;15(7):868-70. doi: 10.1111/codi.12292. No abstract available.

PMID:
23905553
11.

Impact of hydrolysis-mediated clearance on the pharmacokinetics of novel anaplastic lymphoma kinase inhibitors.

Teffera Y, Berry LM, Brake RL, Lewis RT, Saffran DC, Moore E, Liu J, Zhao Z.

Drug Metab Dispos. 2013 Jan;41(1):238-47. doi: 10.1124/dmd.112.047993. Epub 2012 Nov 1.

12.

Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.

Peterson EA, Boezio AA, Andrews PS, Boezio CM, Bush TL, Cheng AC, Choquette D, Coats JR, Colletti AE, Copeland KW, DuPont M, Graceffa R, Grubinska B, Kim JL, Lewis RT, Liu J, Mullady EL, Potashman MH, Romero K, Shaffer PL, Stanton MK, Stellwagen JC, Teffera Y, Yi S, Cai T, La DS.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):4967-74. doi: 10.1016/j.bmcl.2012.06.033. Epub 2012 Jun 16.

PMID:
22765895
13.

The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.

Lewis RT, Bode CM, Choquette DM, Potashman M, Romero K, Stellwagen JC, Teffera Y, Moore E, Whittington DA, Chen H, Epstein LF, Emkey R, Andrews PS, Yu VL, Saffran DC, Xu M, Drew A, Merkel P, Szilvassy S, Brake RL.

J Med Chem. 2012 Jul 26;55(14):6523-40. doi: 10.1021/jm3005866. Epub 2012 Jul 10.

PMID:
22734674
14.

Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.

Bode CM, Boezio AA, Albrecht BK, Bellon SF, Berry L, Broome MA, Choquette D, Dussault I, Lewis RT, Lin MH, Rex K, Whittington DA, Yang Y, Harmange JC.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4089-93. doi: 10.1016/j.bmcl.2012.04.072. Epub 2012 Apr 25.

PMID:
22595176
15.

Rapid development of piperidine carboxamides as potent and selective anaplastic lymphoma kinase inhibitors.

Bryan MC, Whittington DA, Doherty EM, Falsey JR, Cheng AC, Emkey R, Brake RL, Lewis RT.

J Med Chem. 2012 Feb 23;55(4):1698-705. doi: 10.1021/jm201565s. Epub 2012 Feb 9.

PMID:
22263917
16.

1H NMR relaxation of water: a probe for surfactant adsorption on kaolin.

Totland C, Lewis RT, Nerdal W.

J Colloid Interface Sci. 2011 Nov 1;363(1):362-70. doi: 10.1016/j.jcis.2011.07.064. Epub 2011 Jul 27.

PMID:
21840530
17.

Efficacy and complications of surgery for Crohn's disease.

Lewis RT, Maron DJ.

Gastroenterol Hepatol (N Y). 2010 Sep;6(9):587-96.

18.

Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1.

Blackaby WP, Lewis RT, Thomson JL, Jennings AS, Goodacre SC, Street LJ, MacLeod AM, Pike A, Wood S, Thomas S, Brown TA, Smith A, Pillai G, Almond S, Guscott MR, Burns HD, Eng W, Ryan C, Cook J, Hamill TG.

ACS Med Chem Lett. 2010 Jun 25;1(7):350-4. doi: 10.1021/ml1001085. eCollection 2010 Oct 14.

19.

Anorectal Crohn's disease.

Lewis RT, Maron DJ.

Surg Clin North Am. 2010 Feb;90(1):83-97, Table of Contents. doi: 10.1016/j.suc.2009.09.004. Review.

PMID:
20109634
20.

Optimisation of a series of potent, selective and orally bioavailable GlyT1 inhibitors.

Thomson JL, Blackaby WP, Jennings AS, Goodacre SC, Pike A, Thomas S, Brown TA, Smith A, Pillai G, Street LJ, Lewis RT.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2235-9. doi: 10.1016/j.bmcl.2009.02.102. Epub 2009 Feb 28.

PMID:
19318248
21.

A pyridazine series of alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.

Lewis RT, Blackaby WP, Blackburn T, Jennings AS, Pike A, Wilson RA, Hallett DJ, Cook SM, Ferris P, Marshall GR, Reynolds DS, Sheppard WF, Smith AJ, Sohal B, Stanley J, Tye SJ, Wafford KA, Atack JR.

J Med Chem. 2006 Apr 20;49(8):2600-10.

PMID:
16610803
22.

The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagoclone.

Atack JR, Pike A, Marshall G, Stanley J, Lincoln R, Cook SM, Lewis RT, Blackaby WP, Goodacre SC, McKernan RM, Dawson GR, Wafford KA, Reynolds DS.

Neuropharmacology. 2006 May;50(6):677-89. Epub 2006 Jan 20.

PMID:
16430927
23.

Imidazo[1,2-a]pyrimidines as functionally selective GABA(A) ligands.

Blackaby WP, Atack JR, Bromidge F, Castro JL, Goodacre SC, Hallett DJ, Lewis RT, Marshall GR, Pike A, Smith AJ, Street LJ, Tattersall DF, Wafford KA.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1175-9. Epub 2006 Jan 6.

PMID:
16406613
24.

Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disorders.

Goodacre SC, Street LJ, Hallett DJ, Crawforth JM, Kelly S, Owens AP, Blackaby WP, Lewis RT, Stanley J, Smith AJ, Ferris P, Sohal B, Cook SM, Pike A, Brown N, Wafford KA, Marshall G, Castro JL, Atack JR.

J Med Chem. 2006 Jan 12;49(1):35-8.

PMID:
16392789
25.

Imidazo[1,2-b][1,2,4]triazines as alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.

Jennings AS, Lewis RT, Russell MG, Hallett DJ, Street LJ, Castro JL, Atack JR, Cook SM, Lincoln R, Stanley J, Smith AJ, Reynolds DS, Sohal B, Pike A, Marshall GR, Wafford KA, Sheppard WF, Tye SJ.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1477-80. Epub 2006 Jan 4.

PMID:
16386900
26.

Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas.

Kesmodel SB, Karakousis GC, Botbyl JD, Canter RJ, Lewis RT, Wahl PM, Terhune KP, Alavi A, Elder DE, Ming ME, Guerry D, Gimotty PA, Fraker DL, Czerniecki BJ, Spitz FR.

Ann Surg Oncol. 2005 Jun;12(6):449-58. Epub 2005 Apr 19.

PMID:
15864482
28.

PU.1-mediated transcription is enhanced by HMG-I(Y)-dependent structural mechanisms.

Lewis RT, Andreucci A, Nikolajczyk BS.

J Biol Chem. 2001 Mar 23;276(12):9550-7. Epub 2000 Dec 20.

29.

An efficient protocol for the preparation of primary alcohols bearing a beta-chiral center via an oxazolidinone auxiliary mediated resolution, and application to the synthesis of 4,4-disubstituted piperidine substance P antagonists.

Lewis RT, Ladduwahetty T, Merchant KJ, Keown LE, Hitzel L, Verrier H, Stevenson GI, MacLeod AM.

J Org Chem. 2000 Apr 21;65(8):2615-8. No abstract available.

PMID:
10789488
30.

Serine derived NK1 antagonists. 1: The effect of modifications to the serine substituents.

Elliott JM, Cascieri MA, Chicchi G, Davies S, Kelleher FJ, Kurtz M, Ladduwahetty T, Lewis RT, MacLeod AM, Merchant KJ, Sadowski S, Stevenson GI.

Bioorg Med Chem Lett. 1998 Jul 21;8(14):1845-50.

PMID:
9873445
31.

Soft tissue infections.

Lewis RT.

World J Surg. 1998 Feb;22(2):146-51. Review.

PMID:
9451929
32.

Should antibiotic prophylaxis be used routinely in clean surgical procedures: a tentative yes.

Lewis RT, Weigand FM, Mamazza J, Lloyd-Smith W, Tataryn D.

Surgery. 1995 Oct;118(4):742-6; discussion 746-7.

PMID:
7570331
33.

Tryptophan-derived NK1 antagonists: conformationally constrained heterocyclic bioisosteres of the ester linkage.

Lewis RT, Macleod AM, Merchant KJ, Kelleher F, Sanderson I, Herbert RH, Cascieri MA, Sadowski S, Ball RG, Hoogsteen K.

J Med Chem. 1995 Mar 17;38(6):923-33.

PMID:
7699709
34.

Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophan.

MacLeod AM, Cascieri MA, Merchant KJ, Sadowski S, Hardwicke S, Lewis RT, MacIntyre DE, Metzger JM, Fong TM, Shepheard S, et al.

J Med Chem. 1995 Mar 17;38(6):934-41.

PMID:
7535362
35.

Comparison of single-dose cefotetan and multidose cefoxitin as intravenous prophylaxis in elective, open biliary tract surgery: a multicentre, double-blind, randomized study.

Lapointe RW, Roy AF, Turgeon PL, Lewis RT, Dagenais MH, Joly JR, Scudamore CH, Roy PD, Conly JM, Syrotuik J.

Can J Surg. 1994 Aug;37(4):313-8.

PMID:
8055389
36.

Necrotizing soft-tissue infections.

Lewis RT.

Infect Dis Clin North Am. 1992 Sep;6(3):693-703. Review.

PMID:
1431046
37.

Efficacy and distribution of single-dose preoperative antibiotic prophylaxis in high-risk gastroduodenal surgery.

Lewis RT, Goodall RG, Marien B, Park M, Lloyd-Smith W, Wiegand FM.

Can J Surg. 1991 Apr;34(2):117-22.

PMID:
2025800
38.

Simple elective cholecystectomy: to drain or not.

Lewis RT, Goodall RG, Marien B, Park M, Lloyd-Smith W, Wiegand FM.

Am J Surg. 1990 Feb;159(2):241-5. Review.

PMID:
2405730
39.

Is neomycin necessary for bowel preparation in surgery of the colon? Oral neomycin plus erythromycin versus erythromycin-metronidazole.

Lewis RT, Goodall RG, Marien B, Lloyd-Smith W, Park M, Wiegand FM.

Can J Surg. 1989 Jul;32(4):265-70.

PMID:
2660973
40.

Natural history of vertical abdominal parietal closure: Prolene versus Dexon.

Lewis RT, Wiegand FM.

Can J Surg. 1989 May;32(3):196-200.

PMID:
2540896
41.

Cephalosporin therapy in intraabdominal infections. A multicenter randomized, comparative study of cefotetan, moxalactam, and cefoxitin.

Wilson SE, Boswick JA Jr, Duma RJ, Echols RM, Jemsek JG, Lerner R, Lewis RT, Najem AZ, Press RA, Rittenbury MS, et al.

Am J Surg. 1988 May 31;155(5A):61-6.

PMID:
3287971
42.

Comparative study of cefotetan and cefoxitin in the treatment of intra-abdominal infections.

Lewis RT, Duma RJ, Echols RM, Jemsek JG, Najem AZ, Press RA, Stone HH, Ton GT, Wilson SE.

Am J Obstet Gynecol. 1988 Mar;158(3 Pt 2):728-35. Erratum in: Am J Obstet Gynecol 1989 Apr;160(4):1025.

PMID:
3281463
43.

Biliary bacteria, antibiotic use, and wound infection in surgery of the gallbladder and common bile duct.

Lewis RT, Goodall RG, Marien B, Park M, Lloyd-Smith W, Wiegand FM.

Arch Surg. 1987 Jan;122(1):44-7.

PMID:
3800650
44.

The correlation between carotid plaque ulceration and cerebral infarction seen on CT scan.

Zukowski AJ, Nicolaides AN, Lewis RT, Mansfield AO, Williams MA, Helmis E, Malouf GM, Thomas D, Al-Kutoubi A, Kyprianou P, et al.

J Vasc Surg. 1984 Nov;1(6):782-6.

PMID:
6492306
45.
46.

A single preoperative dose of cefazolin prevents postoperative sepsis in high-risk biliary surgery.

Lewis RT, Allan CM, Goodall RG, Marien B, Park M, Lloyd-Smith W, Wiegand FM.

Can J Surg. 1984 Jan;27(1):44-7.

PMID:
6380693
47.

Are first-generation cephalosporins effective for antibiotic prophylaxis in elective surgery of the colon?

Lewis RT, Allan CM, Goodall RG, Marien B, Park M, Lloyd-Smith W, Wiegand FM.

Can J Surg. 1983 Nov;26(6):504-7.

PMID:
6354408
48.

Cefamandole in gastroduodenal surgery: a controlled, prospective, randomized, double-blind study.

Lewis RT, Allan CM, Goodall RG, Marien B, Park M, Lloyd-Smith W, Wiegand FM.

Can J Surg. 1982 Sep;25(5):561-3.

PMID:
6749271
49.

The conduct of cholecystectomy: incision, drainage, bacteriology and postoperative complications.

Lewis RT, Allan CM, Goodall RG, Marien B, Park M, Lloyd-Smith W, Wiegand FM.

Can J Surg. 1982 May;25(3):304-7.

PMID:
7083079
50.

Antibiotic prophylaxis in surgery.

Lewis RT.

Can J Surg. 1981 Nov;24(6):561-6. Review.

PMID:
7034914

Supplemental Content

Loading ...
Support Center